![Sven-Erik Dahlén](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sven-Erik Dahlén
Corporate Officer/Principal at Karolinska Institutet
Sven-Erik Dahlén active positions
Companies | Position | Start | End |
---|---|---|---|
Karolinska Institutet | Corporate Officer/Principal | - | - |
Career history of Sven-Erik Dahlén
Former positions of Sven-Erik Dahlén
Companies | Position | Start | End |
---|---|---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Director/Board Member | 31/12/2004 | 23/06/2010 |
Statistics
International
Sweden | 3 |
Operational
Director/Board Member | 1 |
Corporate Officer/Principal | 1 |
Sectoral
Health Technology | 2 |
Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
Private companies | 1 |
---|---|
Resistentia Pharmaceuticals AB
![]() Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | Health Technology |
- Stock Market
- Insiders
- Sven-Erik Dahlén
- Experience